NasdaqGM:RDHL

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on the development and commercialization of drugs for gastrointestinal diseases.


Snowflake Analysis

High growth potential with mediocre balance sheet.


Similar Companies

Share Price & News

How has RedHill Biopharma's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: RDHL's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

1.0%

RDHL

-0.4%

US Pharmaceuticals

1.3%

US Market


1 Year Return

-7.3%

RDHL

2.8%

US Pharmaceuticals

6.1%

US Market

Return vs Industry: RDHL underperformed the US Pharmaceuticals industry which returned 1.6% over the past year.

Return vs Market: RDHL underperformed the US Market which returned 6.7% over the past year.


Shareholder returns

RDHLIndustryMarket
7 Day1.0%-0.4%1.3%
30 Day-10.3%-2.7%-0.3%
90 Day13.4%1.6%16.6%
1 Year-7.3%-7.3%5.5%2.8%8.4%6.1%
3 Year-22.1%-22.1%23.1%14.1%35.8%26.9%
5 Year-57.8%-57.8%25.2%10.8%62.7%44.7%

Price Volatility Vs. Market

How volatile is RedHill Biopharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is RedHill Biopharma undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: RDHL ($6.86) is trading below our estimate of fair value ($81.94)

Significantly Below Fair Value: RDHL is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: RDHL is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: RDHL is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate RDHL's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: RDHL is overvalued based on its PB Ratio (5.5x) compared to the US Pharmaceuticals industry average (3.4x).


Next Steps

Future Growth

How is RedHill Biopharma forecast to perform in the next 1 to 3 years based on estimates from 6 analysts?

67.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: RDHL is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.2%).

Earnings vs Market: RDHL is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: RDHL's is expected to become profitable in the next 3 years.

Revenue vs Market: RDHL's revenue (38.8% per year) is forecast to grow faster than the US market (9.3% per year).

High Growth Revenue: RDHL's revenue (38.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if RDHL's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has RedHill Biopharma performed over the past 5 years?

-16.7%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: RDHL is currently unprofitable.

Growing Profit Margin: RDHL is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: RDHL is unprofitable, and losses have increased over the past 5 years at a rate of -16.7% per year.

Accelerating Growth: Unable to compare RDHL's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RDHL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (16.1%).


Return on Equity

High ROE: RDHL has a negative Return on Equity (-113.62%), as it is currently unprofitable.


Next Steps

Financial Health

How is RedHill Biopharma's financial position?


Financial Position Analysis

Short Term Liabilities: RDHL's short term assets ($101.0M) exceed its short term liabilities ($17.3M).

Long Term Liabilities: RDHL's short term assets ($101.0M) exceed its long term liabilities ($82.5M).


Debt to Equity History and Analysis

Debt Level: RDHL's debt to equity ratio (179.1%) is considered high.

Reducing Debt: Insufficient data to determine if RDHL's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: RDHL has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if RDHL has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Next Steps

Dividend

What is RedHill Biopharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate RDHL's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate RDHL's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RDHL's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RDHL's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RDHL's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

4.3yrs

Average management tenure


CEO

Dror Ben-Asher (54yo)

10.92yrs

Tenure

US$707,922

Compensation

Mr. Dror Ben-Asher Co-Founded RedHill Biopharma Ltd. and has been its Chief Executive Officer since August 3, 2009. Mr. Ben-Asher serves as an Associate of Mercator Group, LLC. He has been affiliated with  ...


CEO Compensation Analysis

Compensation vs Market: Dror's total compensation ($USD707.92K) is below average for companies of similar size in the US market ($USD1.34M).

Compensation vs Earnings: Dror's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Dror Ben-Asher
Co-Founder10.92yrsUS$707.92k0.93% $2.3m
Micha Ben-Chorin
Chief Financial Officer4.33yrsUS$505.51kno data
Gilead Raday
Chief Operating Officer4.25yrsUS$539.28kno data
Adi Frish
Senior Vice President of Business Development & Licensing7.58yrsUS$504.62k0.051% $123.5k
Guy Goldberg
Chief Business Officer8yrsUS$504.63kno data
June Almenoff
Chief Scientific Officer1.17yrsno data0.0020% $4.9k
Shani Maurice
Vice President of Business Development & Communications4.17yrsno datano data
Valerie Graceffa
Vice President of Salesno datano datano data
Rob Jackson
Vice President of Marketing1.17yrsno datano data
Reza Fathi
Senior Vice President of Research & Development10.17yrsUS$419.98k0.077% $185.2k

4.3yrs

Average Tenure

51yo

Average Age

Experienced Management: RDHL's management team is considered experienced (4.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Dror Ben-Asher
Co-Founder10.92yrsUS$707.92k0.93% $2.3m
Rick Scruggs
Chief Commercial Officer4.5yrsno datano data
Harry Leighton
Chairman of Advisory Boardno datano datano data
Ofer Tsimchi
Independent External Director9.17yrsno datano data
Ira Kalfus
Member of Advisory Board1.5yrsno datano data
Shmuel Cabilly
Director0.83yrno data1.43% $3.5m
Yechezkel Barenholz
Member of Advisory Boardno datano datano data
Ran Oren
Member of Advisory Boardno datano datano data
Eric Swenden
Director10.17yrsno data0.30% $726.5k
Kenneth Reed
Director10.58yrsno data2.09% $5.1m

9.2yrs

Average Tenure

63yo

Average Age

Experienced Board: RDHL's board of directors are considered experienced (9.2 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 24.3%.


Top Shareholders

Company Information

RedHill Biopharma Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: RedHill Biopharma Ltd.
  • Ticker: RDHL
  • Exchange: NasdaqGM
  • Founded: 2009
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$241.949m
  • Shares outstanding: 35.27m
  • Website: https://www.redhillbio.com

Number of Employees


Location

  • RedHill Biopharma Ltd.
  • 21 Ha’arba’a Street
  • Tel Aviv
  • 6473921
  • Israel

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
REDI.FOTCPK (Pink Sheets LLC)Ordinary SharesUSUSDFeb 2011
RDHLNasdaqGM (Nasdaq Global Market)YesSPONSORED ADSUSUSDDec 2012
2RHDB (Deutsche Boerse AG)YesSPONSORED ADSDEEURDec 2012

Biography

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on the development and commercialization of drugs for gastrointestinal diseases. The company promotes various gastrointestinal drugs, including Movantik for opioid-induced constipation in adults; Talicia for the treatment of Helicobacter pylori bacterial infection in adults; and Aemcolo for the treatment of travelers’ diarrhea in adults. Its late-stage clinical development programs include RHB-104, which is in Phase 3 study for treating Crohn's disease; RHB-204, with a planned pivotal Phase 3 study for pulmonary nontuberculous mycobacteria infections; RHB-102 (Bekinda) that is in first Phase 3 study to treat acute gastroenteritis and gastritis, as well as has completed Phase 2 study for treating irritable bowel syndrome with diarrhea; RHB-106, which is in planned Phase 2/3 studies for bowel preparation; ABC294640 (Yeliva), a SK2 selective inhibitor, which is in Phase 1/2a study for treating cholangiocarcinoma, as well as in Phase 2 study for prostate cancer; and RHB-107 that is in planned pilot study for cholangiocarcinoma, as well as has completed Phase 2 study for gastrointestinal and other solid tumors. The company was founded in 2009 and is headquartered in Tel Aviv, Israel. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/10 00:04
End of Day Share Price2020/07/09 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.